drugset / Trial / NCT02076620
L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours
NaSingle-groupOpen-labelTreatment
Summary
Prospective, open-label, non randomized, dose escalation study that will be conducted in sequential cohorts of patients.
Timeline
- Start
- 2013-01-16
- Primary completion
- 2018-01-25
- Completion
- 2018-01-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | L19TNFα | Protein / enzyme biologic | 10.4 ug/kg | Intravenous |
| Subject | L19TNFα | Protein / enzyme biologic | 13 ug/kg | Intravenous |
| Subject | L19TNFα | Protein / enzyme biologic | 17 ug/kg | Intravenous |
| Background | Doxorubicin | Other / unclassified | 60 mg/m2 | Intravenous |
Indications
No indication recorded.